The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase 0 trial of the mitochondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC).
 
Miguel Quintela-Fandino
Consulting or Advisory Role - Bayer Health
Research Funding - AstraZeneca; Bayer Health; Boehringer Ingelheim; Merck Sharp & Dome; Roche
 
Serafin Morales
No Relationships to Disclose
 
Alfonso Cortes Salgado
No Relationships to Disclose
 
Luis Manso
No Relationships to Disclose
 
Juan V Apala
No Relationships to Disclose
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Daiichi Sankyo; ERYTECH Pharma; Merus; Polyphor; Roche; Seagen
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Pique (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer; Roche
 
Juan Antonio Guerra
No Relationships to Disclose
 
Eduardo Caleiras
No Relationships to Disclose
 
Francisca Mulero
No Relationships to Disclose
 
Silvana Andrea Mouron
No Relationships to Disclose